HRP20182159T1 - Poboljšane formulacije adenovirusa - Google Patents

Poboljšane formulacije adenovirusa

Info

Publication number
HRP20182159T1
HRP20182159T1 HRP20182159TT HRP20182159T HRP20182159T1 HR P20182159 T1 HRP20182159 T1 HR P20182159T1 HR P20182159T T HRP20182159T T HR P20182159TT HR P20182159 T HRP20182159 T HR P20182159T HR P20182159 T1 HRP20182159 T1 HR P20182159T1
Authority
HR
Croatia
Prior art keywords
improved adenovirus
adenovirus formulations
formulations
improved
adenovirus
Prior art date
Application number
HRP20182159TT
Other languages
English (en)
Inventor
Janik ADRIAANSEN
Original Assignee
Janssen Vaccines & Prevention B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49212683&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20182159(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Vaccines & Prevention B.V. filed Critical Janssen Vaccines & Prevention B.V.
Publication of HRP20182159T1 publication Critical patent/HRP20182159T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Detergent Compositions (AREA)
HRP20182159TT 2013-09-19 2018-12-19 Poboljšane formulacije adenovirusa HRP20182159T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13185200 2013-09-19
EP14766474.2A EP3046536B1 (en) 2013-09-19 2014-09-16 Improved adenovirus formulations
PCT/EP2014/069654 WO2015040002A1 (en) 2013-09-19 2014-09-16 Improved adenovirus formulations

Publications (1)

Publication Number Publication Date
HRP20182159T1 true HRP20182159T1 (hr) 2019-02-22

Family

ID=49212683

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20182159TT HRP20182159T1 (hr) 2013-09-19 2018-12-19 Poboljšane formulacije adenovirusa

Country Status (32)

Country Link
US (3) US9974737B2 (hr)
EP (1) EP3046536B1 (hr)
JP (1) JP6013654B2 (hr)
KR (1) KR102258348B1 (hr)
CN (2) CN111514314A (hr)
AP (1) AP2016009154A0 (hr)
AU (1) AU2014323230B2 (hr)
BR (1) BR112016005761B1 (hr)
CA (1) CA2923352C (hr)
CL (1) CL2016000621A1 (hr)
CY (1) CY1122796T1 (hr)
DK (1) DK3046536T3 (hr)
EA (1) EA036046B1 (hr)
ES (1) ES2711115T3 (hr)
HR (1) HRP20182159T1 (hr)
HU (1) HUE041791T2 (hr)
IL (1) IL244572A (hr)
LT (1) LT3046536T (hr)
ME (1) ME03324B (hr)
MX (1) MX369156B (hr)
MY (1) MY181190A (hr)
NZ (1) NZ717156A (hr)
PE (1) PE20160527A1 (hr)
PH (1) PH12016500316A1 (hr)
PL (1) PL3046536T3 (hr)
PT (1) PT3046536T (hr)
RS (1) RS58393B1 (hr)
SG (1) SG11201601181SA (hr)
SI (1) SI3046536T1 (hr)
TR (1) TR201900274T4 (hr)
WO (1) WO2015040002A1 (hr)
ZA (1) ZA201601919B (hr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA039803B1 (ru) 2013-04-25 2022-03-15 Янссен Вэксинс Энд Превеншн Б.В. Стабилизированные растворимые f-полипептиды rsv до слияния
EP3561062A1 (en) 2013-09-13 2019-10-30 California Institute of Technology Selective recovery
CA2923352C (en) * 2013-09-19 2022-05-03 Crucell Holland B.V. Stable adenovirus formulations
EA035909B1 (ru) 2015-07-07 2020-08-31 Янссен Вэксинс Энд Превеншн Б.В. Стабилизированные растворимые f-полипептиды rsv до слияния
PL3319633T3 (pl) 2015-07-07 2021-04-19 Janssen Vaccines & Prevention B.V. Szczepionka przeciwko rsv
EP3359132B1 (en) * 2015-10-06 2023-08-16 Janssen Vaccines & Prevention B.V. Methods for preventing plastic-induced degradation of biologicals
CN108699565B (zh) 2015-12-11 2023-08-08 加州理工学院 用于定向腺相关病毒(aav)的靶向肽
EA201892250A1 (ru) 2016-04-05 2019-03-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
JP7088841B2 (ja) 2016-04-05 2022-06-21 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定化された可溶性融合前ｒｓｖ ｆタンパク質
EP3464331B1 (en) 2016-05-30 2020-10-28 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
EP3624844A1 (en) 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
SG11202001458SA (en) 2017-09-15 2020-03-30 Janssen Vaccines & Prevention Bv Method for the safe induction of immunity against rsv
AU2019346447A1 (en) 2018-09-26 2021-04-29 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
WO2020145872A1 (en) * 2019-01-09 2020-07-16 Ziccum Ab Stabilized non-enveloped virus compositions
CN117999353A (zh) * 2021-07-08 2024-05-07 拜奥卡德联合股份公司 无包膜病毒的药物组合物
WO2023240196A1 (en) * 2022-06-08 2023-12-14 Gritstone Bio, Inc. Compositions and methods of use thereof
EP4338727A1 (en) 2022-09-14 2024-03-20 Roquette Freres Adenovirus formulations
WO2024079657A1 (en) * 2022-10-11 2024-04-18 Meiragtx Uk Ii Limited Formulations for aav gene therapy

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
DE69535178T2 (de) 1994-06-10 2006-12-14 Genvec, Inc. Adenoviren-vektor systeme und zelllinien
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
JP4051416B2 (ja) 1995-06-15 2008-02-27 クルーセル ホランド ベスローテン フェンノートシャップ 遺伝子治療に使用されるヒト組換えアデノウイルス用のパッケージングシステム
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
EP1977764A1 (en) * 1998-11-16 2008-10-08 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) * 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US7456009B2 (en) * 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
JP5118798B2 (ja) * 2000-03-07 2013-01-16 メルク・シャープ・エンド・ドーム・コーポレイション アデノウイルス製剤
CA2469623C (en) * 2001-12-12 2012-05-29 F H Faulding & Co Limited Composition for the preservation of viruses
SI1456377T1 (sl) * 2001-12-20 2019-09-30 Merck Sharp & Dohme Corp. Sestavki SYN3 in postopki
US20030180936A1 (en) * 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
ES2335657T3 (es) 2002-04-25 2010-03-31 Crucell Holland B.V. Medios y metodos para la produccion de vectores de adenovirus.
WO2004055187A1 (en) 2002-12-17 2004-07-01 Crucell Holland B.V. Recombinant viral-based malaria vaccines
CN1845932A (zh) 2003-06-04 2006-10-11 坎基股份有限公司 转染剂
WO2005012407A2 (en) * 2003-06-30 2005-02-10 Canji, Inc. Polymer encapsulation of adenoviruses
WO2005052116A2 (en) * 2003-11-19 2005-06-09 Merck & Co., Inc. Preservative-containing virus formulations
KR101386690B1 (ko) * 2004-03-04 2014-04-22 도쿠리츠교세이호진 고쿠리츠간켄큐센터 래트 배아 줄기 세포
CA2586620C (en) 2004-11-16 2014-06-03 Crucell Holland B.V. Multivalent vaccines comprising recombinant viral vectors
CN1883707A (zh) * 2006-05-19 2006-12-27 吉林大学 重组腺病毒的冻干制剂及其制备方法
GB0715723D0 (en) * 2007-08-11 2007-09-19 Ark Therapeutics Ltd Formulation
US20110059079A1 (en) * 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody Coformulations
GB201002419D0 (en) 2010-02-12 2010-03-31 Isis Innovation Stable live vaccine formulations
WO2012110971A2 (en) 2011-02-17 2012-08-23 Promed Exports Pvt. Ltd. Method and composition to retard sorption of preservatives to plastics
CA2923352C (en) * 2013-09-19 2022-05-03 Crucell Holland B.V. Stable adenovirus formulations
CN104027815A (zh) 2014-06-12 2014-09-10 中国农业科学院兰州畜牧与兽药研究所 一种丹参酮包合液及其制备方法和应用
EP3359132B1 (en) 2015-10-06 2023-08-16 Janssen Vaccines & Prevention B.V. Methods for preventing plastic-induced degradation of biologicals

Also Published As

Publication number Publication date
KR20160055180A (ko) 2016-05-17
PH12016500316B1 (en) 2016-05-02
EP3046536B1 (en) 2018-11-28
JP6013654B2 (ja) 2016-10-25
CA2923352A1 (en) 2015-03-26
RS58393B1 (sr) 2019-04-30
US9974737B2 (en) 2018-05-22
KR102258348B1 (ko) 2021-05-31
AU2014323230B2 (en) 2017-05-25
PL3046536T3 (pl) 2019-06-28
EA201690613A1 (ru) 2016-08-31
IL244572A (en) 2017-02-28
US20190240146A1 (en) 2019-08-08
HUE041791T2 (hu) 2019-05-28
CN105530917B (zh) 2020-06-05
DK3046536T3 (en) 2019-03-11
SG11201601181SA (en) 2016-04-28
MX369156B (es) 2019-10-30
AP2016009154A0 (en) 2016-04-30
US20180235871A1 (en) 2018-08-23
MX2016003414A (es) 2016-06-30
EP3046536A1 (en) 2016-07-27
ZA201601919B (en) 2017-06-28
BR112016005761A2 (hr) 2017-08-01
ES2711115T3 (es) 2019-04-30
US11484494B2 (en) 2022-11-01
PE20160527A1 (es) 2016-05-20
IL244572A0 (en) 2016-04-21
SI3046536T1 (sl) 2019-05-31
LT3046536T (lt) 2019-03-12
JP2016530220A (ja) 2016-09-29
US20160199426A1 (en) 2016-07-14
CN105530917A (zh) 2016-04-27
AU2014323230A1 (en) 2016-03-17
WO2015040002A1 (en) 2015-03-26
CY1122796T1 (el) 2021-05-05
US10272032B2 (en) 2019-04-30
ME03324B (me) 2019-10-20
PT3046536T (pt) 2019-02-25
CN111514314A (zh) 2020-08-11
CA2923352C (en) 2022-05-03
TR201900274T4 (tr) 2019-02-21
CL2016000621A1 (es) 2016-11-25
BR112016005761B1 (pt) 2022-09-20
MY181190A (en) 2020-12-21
PH12016500316A1 (en) 2016-05-02
EA036046B1 (ru) 2020-09-18
NZ717156A (en) 2022-04-29

Similar Documents

Publication Publication Date Title
HRP20182159T1 (hr) Poboljšane formulacije adenovirusa
EP3065716C0 (en) FORMULATIONS
IL240723A0 (en) A vaccine
HK1219061A1 (zh) 乳液製劑
PT3071638T (pt) Composição de cianoacrilato
SG11201507393TA (en) Oncolytic adenovirus compositions
GB201319792D0 (en) Formulations
EP2961397A4 (en) TRANSDERMAL FORMULATIONS
HK1224228A1 (zh) 新型製劑
HK1214951A1 (zh) 眼用製劑
GB201320432D0 (en) Novel formulation
SG11201509194SA (en) Radiomitigating pharmaceutical formulations
EP2999689A4 (en) CYANOACRYLATE COMPOSITIONS
GB201322948D0 (en) Improved formulation
HK1220366A1 (zh) 蛋白製劑
GB2517232B (en) Formulation
GB201317718D0 (en) Novel formulation
GB201313688D0 (en) Improved cyanoacrylate compositions
SG11201604136PA (en) Improved formulations for virosomes
PT3041488T (pt) Composições de mel
GB201318885D0 (en) Adenovirus
GB201318880D0 (en) Adenovirus
HK1209981A1 (en) Formulation
EP2986109A4 (en) IMPROVED ECTOPARASITICIDE FORMULATIONS
GB201317717D0 (en) Novel formulation